93 filings
8-K
COLL
Collegium Pharmaceutical Inc
10 May 24
Departure of Directors or Certain Officers
8:02am
8-K
COLL
Collegium Pharmaceutical Inc
9 May 24
Collegium Reports First Quarter 2024 Financial Results
4:04pm
8-K
COLL
Collegium Pharmaceutical Inc
29 Apr 24
Entry into a Material Definitive Agreement
8:05am
8-K
COLL
Collegium Pharmaceutical Inc
11 Apr 24
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
8:00am
8-K
COLL
Collegium Pharmaceutical Inc
22 Feb 24
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
4:01pm
8-K
bzqln1zmybubjftjj5
3 Jan 24
Regulation FD Disclosure
8:03am
8-K
zl11zzt 73jferp
9 Nov 23
Other Events
8:05am
8-K
d1gsp3j0 zydw
7 Nov 23
Collegium Reports Third Quarter 2023 Financial Results
4:01pm
8-K
5h4yttimg1qvuld
24 Aug 23
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
8:05am
8-K
r0owvq
7 Aug 23
Other Events
7:40am
8-K
exdnhmh4qwle myc9s
3 Aug 23
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
4:03pm
8-K
mm88rzqnwub 21
19 May 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
48y4eb1ssp2ri
4 May 23
Collegium Reports First Quarter 2023 Financial Results
4:01pm
8-K
0mnxph9dufimlj2ni
23 Feb 23
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
4:01pm
8-K
5gqpob7ipey
13 Feb 23
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
4:05pm
8-K
p4hvnb7dh8xd
6 Feb 23
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
4:14pm
8-K
gdmcxxr
4 Jan 23
Regulation FD Disclosure
8:04am
8-K
q64gt6n qlh
22 Dec 22
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
8:04am
8-K
ts36b41e
3 Nov 22
Collegium Reports Third Quarter 2022 Financial Results
4:01pm
8-K
hu18rktb68pg0mzy0
4 Aug 22
Collegium Reports Second Quarter 2022 Financial Results
4:01pm